OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Goldberg on the Toxicity Profile of Amivantamab in Metastatic EGFR Exon 20–Mutant NSCLC

March 2nd 2021

Sarah B. Goldberg, MD, MPH, discusses the toxicity profile associated with amivantamab in metastatic non–small cell lung cancer that harbors EGFR exon 20 insertion mutations.

Dr. Singal on the Utility of Frontline Lenvatinib and Sorafenib in Advanced HCC

March 2nd 2021

Amit G. Singal, MD, MS, discusses the utility of frontline lenvatinib and sorafenib in hepatocellular carcinoma.

Dr. Richardson on the FDA Approval of Melphalan Flufenamide in Relapsed/Refractory Multiple Myeloma

March 1st 2021

Paul G. Richardson, MD, discusses the FDA approval of melphalan flufenamide in relapsed/refractory multiple myeloma.

Dr. Krivak on the Importance of Germline Genetic Testing in Ovarian Cancer

March 1st 2021

Thomas C. Krivak, MD, discusses the importance of germline genetic testing in ovarian cancer.

Dr. Martin on Potential Combination Strategies With BTK Inhibitors in MCL

March 1st 2021

Peter Martin, MD, discusses potential combination regimens with BTK inhibitors in mantle cell lymphoma.

Dr. Dhakal on the Mechanism of Action of Orva-Cel in Multiple Myeloma

February 26th 2021

Binod Dhakal, MD, discusses the mechanism of action of orvacabtagene autoleucel in multiple myeloma.

Dr. Ip on the Challenges of Treating Patients With Hematologic Malignancies and COVID-19

February 25th 2021

Andrew Ip, MD, MS, discusses the challenges of treating patients with hematologic malignancies and COVID-19.

Dr. del Rio on Selecting Between Available Vaccines for COVID-19

February 25th 2021

Carlos del Rio, MD, discusses factors to consider when selecting between available vaccines for COVID-19.

Dr. Davies on the Utility of Retreatment With BRAF/MEK Inhibitors in BRAF-Mutant Melanoma

February 24th 2021

Michael A. Davies, MD, PhD, discusses the utility of retreatment with combination BRAF/MEK inhibitors in BRAF-mutant melanoma.

Dr. Bociek on the Evolving Role of Prognostic Factors in CLL

February 24th 2021

R. Gregory Bociek, MD, discusses the evolving role of prognostic factors in chronic lymphocytic leukemia.

Dr. Trent on the Need for Novel Combination Strategies in Metastatic GIST

February 24th 2021

Jonathan C. Trent, MD, PhD, discusses the need to develop novel combination strategies for the treatment of patients with metastatic gastrointestinal stromal tumors.

Dr. Naing on the Potential Implications of Immune-Related Adverse Effects in Cancer

February 23rd 2021

Aung Naing, MD, FACP, discusses potential immune-related adverse effects in oncology.

Dr. Nooka on the Utility of BCMA as a Target in Multiple Myeloma

February 23rd 2021

Ajay K. Nooka, MD, MPH, FACP, discusses the utility of BCMA as a target in multiple myeloma.

Dr. Lee on Potential Challenges With VLS-101 in MCL and DLBCL

February 22nd 2021

Hun Ju Lee, MD, discusses potential challenges with VLS-101 in mantle cell lymphoma and diffuse large B-cell lymphoma.

Dr. Bociek on the Evolving Role of Chemoimmunotherapy in CLL

February 22nd 2021

R. Gregory Bociek, MD, discusses the evolving role of chemoimmunotherapy in chronic lymphocytic leukemia.

Dr. Angiolillo on the Toxicity Profile of Traditional Treatment in Pediatric B-ALL

February 22nd 2021

Anne Angiolillo, MD, discusses the adverse effects that are associated with traditional treatment in pediatric B-cell acute lymphoblastic leukemia.

Dr. Sezer on the FDA Approval of Cemiplimab in Frontline Advanced NSCLC With High PD-L1 Expression

February 22nd 2021

Ahmet Sezer, MD, professor, Department of Medical Oncology, Başkent University, Adana, Turkey, discusses the FDA approval of cemiplimab-rwlc (Libtayo) as frontline treatment for patients with advanced non–small cell lung cancer (NSCLC) and high PD-L1 expression.

Dr. Piotrowska on the Utility of Mobocertinib in EGFR Exon 20–Mutant NSCLC

February 19th 2021

Zofia Piotrowska, MD, MHS, discusses the utility of mobocertinib in patients with non–small cell lung cancer who harbor EGFR exon 20 insertions.

Dr. Callander on the Potential Future of Belantamab Mafodotin in Multiple Myeloma

February 19th 2021

Natalie S. Callander, MD, discusses the potential future of belantamab mafodotin-blmf in multiple myeloma.

Dr. Dasari on the Rationale for the FRESCO-2 Trial With Fruquintinib in mCRC

February 19th 2021

Nageshwara Arvind Dasari, MD, discusses the rationale to evaluate fruquintinib in the ongoing, phase 3 FRESCO-2 trial in patients with metastatic colorectal cancer.